Sarasin & Partners LLP Monte Rosa Therapeutics, Inc. Transaction History
Sarasin & Partners LLP
- $11.3 Billion
- Q2 2024
A detailed history of Sarasin & Partners LLP transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Sarasin & Partners LLP holds 65,081 shares of GLUE stock, worth $336,468. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,081
Previous 65,081
-0.0%
Holding current value
$336,468
Previous $458,000
46.94%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GLUE
# of Institutions
77Shares Held
40.6MCall Options Held
84.2KPut Options Held
20.6K-
Nea Management Company, LLC Timonium, MD7.69MShares$39.8 Million2.72% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.98MShares$30.9 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$25.4 Million0.24% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.54MShares$23.4 Million0.23% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.66MShares$13.7 Million0.42% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $242M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...